Result
-€1.1m -€1.1m
From profit to loss in 2025, after a profit of €68.1m in 2024.
INTERNATIONAL DRUG DEVELOPMENT INSTITUTE
Lifetime
20 annual accounts with figures on one time axis, 37 filings since 1989peak €15.3m (2023)
€11.9m▼ 12.5%
lowest -€1.1m (2025)
-€1.1m▼ €69.2m
peak €21.0m (2025)
€21.0m▲ 1.5%
€6.6m▼ 88.0%
peak 98.9 FTE (2023)
74.8 FTE▼ 10.5%
Board24 names since 2005all names
4 directorsActria and 3 others
Owners3 names in the annual accounts
via 99.99%CLINIMETRICS and 1 other
Documentsfilings and deeds
16-06-202645 days before the deadline
2025financial year
Turnover from €13.6m to €11.9mLoss of €1.1mStaff from 83.6 FTE to 74.8 FTEResignation: Tim Davis (daily management delegate) 30-121 director appointed, 4 resignations 30-10Permanent representatives: Damien Tremolet and Linda Danielson 30-01
Key points
from the 2025 annual accountsInvestments
€541,329 2.4 × depreciation
Green is investment, beige is depreciation.
Staff
74 employees on 31-12-2025
In 2025, 2 people joined and 13 left.
Payment terms
89 days to suppliers
INTERNATIONAL DRUG DEVELOPMENT INSTITUTE pays its suppliers 35 days later than in 2024. Customers pay 46 days later.
Liquidity
7.97 was 1.42 in 2024
Short-term debts fell from €53.3m to €3.4m.
Position in the sector
-€1.1m
Lower net result than 95% of companies in human health. Sector median €70,723 · 778 companies.
Checked score
93
Excellent
Financially stronger than 43% of medium-sized companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 84 companies (NACE 86, medium-sized).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.1%▲ +0.1 percentage points vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.2%▲ +0.1 percentage points vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026highest value
07-2026: 0.1%▼ -0.1 percentage points vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Loss of €1.1m (financial year 2025)
1 of the last 3 accounts late
Liquidity: current ratio 7.97, cash €1.3m
lowers risk
Sector: Human health activities (NACE 86)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, medium-sized). It does better than 81% of them on solvency, 53% on liquidity, 9% on profitability and 28% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 830 companies had the same profile as INTERNATIONAL DRUG DEVELOPMENT INSTITUTE has now. Each dot stands for 3 companies, two years later.
96.5%
were still trading
2.9%
stopped another way
0.6%
went bankrupt
That fits the bankruptcy probability of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 830 companies, not a prediction for INTERNATIONAL DRUG DEVELOPMENT INSTITUTE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €1,150,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 7.97 (1.42 in 2024), above the usual 1.5. Short-term debt is 12% and cash 4.7% of total assets. 26.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-06-2026, 45 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
45 days early
2024
277 days late
2023
47 days early
2022
41 days early
2021
47 days early
2020
43 days early
2019
46 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 1 day after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 16 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- Bright Roads 97.15%equity €14.8m (2025) · 2025 annual accounts of Bright Roads
- CLINIMETRICSscore 87equity €192.5m (2025) · 2025 annual accounts of CLINIMETRICS
Shares in 1 company, I.D.D.I. INC.
Board & ownershipRecent changes
Resignation: Tim Davis (daily management delegate)
Board meeting of 03-12-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0436264032
1 director appointed, 4 resignations
Change of role: IDDI GROUP, from director to sole director · Resignations: CLINIMETRICS, Amy Furlong, Linda Beneze and Rob Nichols · Permanent representatives: Damien TREMOLET and Marc BUYSE · General meeting of 22-10-2025 · Gazette deed
Permanent representatives: Damien Tremolet and Linda Danielson
Board meeting of 21-11-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| INTERNATIONAL DRUG DEVELOPMENT INSTITUTE Ottignies-Louvain-la-Neuve | €11.9m | -16.9% | 73.7% | 74.8 |
| Medisch Labo Bruyland Kortrijk | €26.7m | 26.3% | 14.9% | 53.6 |
| GALEPHAR M/F Marche-en-Famenne | €10.8m | 42.4% | 90.8% | 38.8 |
| Sociaal-Medisch Instituut der Zuiderkempen Heist-op-den-Berg | €19.3m | 5.5% | 86.1% | 88.1 |
| LABORATOIRE DE L'INSTITUT MEDICAL SPECIALISE Ottignies-Louvain-la-Neuve | €37.9m | -14.3% | -25.9% | 191.8 |
| bioMérieux Benelux Schaerbeek | €33.3m | 4.4% | - | 69.9 |
| Medisch Centrum voor Huisartsen Leuven | €24.5m | 3.4% | 50.5% | 119.9 |
Grey: the largest companies of the sector (human health (NACE 86)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as INTERNATIONAL DRUG DEVELOPMENT INSTITUTE: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €19m and €32m, founded between 1968 and 1998.
Official details
Source: KBO- Status
- Active since 26-12-1988Normal situation
- Activity
- Medical imaging and medical laboratoriesNACE 86910and 1 other
- Joint committees
- 200Auxiliary committee for white-collar workers
- 100Auxiliary committee for blue-collar workers · annual accounts 2025
- Establishment unit
- 2.041.499.5131341 Ottignies-Louvain-la-Neuve, since 06-01-1989
- Financial year end
- 31 December
- Peppol
- Reachable since 29-12-2025
Annual accounts 2025
- €28.5m▼ 62.8%
- Employeeson 31-12-2025
- 74▼ 12.9%
- Filing
- Filed on 16-06-2026, 45 days before the end of the filing period
Insights on INTERNATIONAL DRUG DEVELOPMENT INSTITUTE
INTERNATIONAL DRUG DEVELOPMENT INSTITUTE has existed since 1988. Turnover grew from €7.2m in 2012 to €11.9m in 2025 and staff from 47.7 to 74.8 full-time equivalents.
Solvency rose in 2025 from 27.0% to 73.7% because of lower debts.
Bright Roads holds 97.15% of the shares. In October 2025, four directors stepped down. In October 2025, the Official Gazette published the appointment of Timothy Davis as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about INTERNATIONAL DRUG DEVELOPMENT INSTITUTE
- What is the company number of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?
- The company number of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is 0436.264.032. The VAT number is the same number with BE in front: BE 0436.264.032.
- Where is INTERNATIONAL DRUG DEVELOPMENT INSTITUTE based?
- The registered office is at Avenue Provinciale 30, 1341 Ottignies-Louvain-la-Neuve.Company details
- What does INTERNATIONAL DRUG DEVELOPMENT INSTITUTE do?
- According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
- What is the legal form of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?
- INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is a public limited company (NV).
- When was INTERNATIONAL DRUG DEVELOPMENT INSTITUTE founded?
- INTERNATIONAL DRUG DEVELOPMENT INSTITUTE was founded on 26-12-1988.
- Is INTERNATIONAL DRUG DEVELOPMENT INSTITUTE still active?
- Yes, INTERNATIONAL DRUG DEVELOPMENT INSTITUTE is an active enterprise in the KBO register.
- How many employees does INTERNATIONAL DRUG DEVELOPMENT INSTITUTE have?
- INTERNATIONAL DRUG DEVELOPMENT INSTITUTE had an average of 74.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does INTERNATIONAL DRUG DEVELOPMENT INSTITUTE fall under?
- In its 2025 annual accounts, INTERNATIONAL DRUG DEVELOPMENT INSTITUTE states joint committees 200 (Auxiliary committee for white-collar workers) and 100 (Auxiliary committee for blue-collar workers).
- What is the turnover of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?
- The turnover of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE was €11.9m in financial year 2025, according to the filed annual accounts.
- Is INTERNATIONAL DRUG DEVELOPMENT INSTITUTE profitable?
- In financial year 2025, INTERNATIONAL DRUG DEVELOPMENT INSTITUTE made a loss of €1.1m.
- Where can I find the annual accounts of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE?
- INTERNATIONAL DRUG DEVELOPMENT INSTITUTE filed 37 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of INTERNATIONAL DRUG DEVELOPMENT INSTITUTE due?
- INTERNATIONAL DRUG DEVELOPMENT INSTITUTE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.